Related stories
Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary an approval for its New Drug
Application (NDA) for DOCEFREZTM (docetaxel) for Injection, 20 mg/vial and 80 mg/vial.
This NDA provides for the use of DOCEFREZTM (docetaxel) for Injection, 20 mg/vial and 80 mg/vial for locally
advanced or metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer and hormone
refractory metastatic prostate cancer
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Media Packs
Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!
– Access the Media Pack Now
– Book a Conference Call
– Leave Message for Us to Get Back
Latest stories
Related stories
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Media Packs
Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!
– Access theMedia Pack Now
– Book a Conference Call
– Leave Message for Us to Get Back
World Pharma Today is a leading Magazine featuring latest industry developments for the Pharmaceutical C-level executives. . . Read More
Copyright © 2010-2026 World Pharma Today. All rights reserved. Publication of Leo Marcom Pvt Ltd.
